Pacira Biosciences (NASDAQ:PCRX) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Pacira Biosciences (NASDAQ:PCRX) from a strong sell rating to a sell rating in a report issued on Wednesday, September 18th, BidAskClub reports.

Several other equities analysts have also commented on PCRX. Wedbush set a $85.00 price target on shares of Pacira Biosciences and gave the stock a buy rating in a research report on Friday, June 28th. Stifel Nicolaus set a $42.00 price target on shares of Pacira Biosciences and gave the stock a hold rating in a research report on Friday, August 9th. BMO Capital Markets dropped their price target on shares of Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research report on Friday, August 9th. Zacks Investment Research raised shares of Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price objective for the company in a research report on Friday, August 2nd. Finally, Barclays assumed coverage on shares of Pacira Biosciences in a research report on Tuesday, June 11th. They issued an overweight rating and a $52.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $55.00.

Shares of NASDAQ PCRX traded up $0.92 on Wednesday, hitting $37.69. The company’s stock had a trading volume of 447,930 shares, compared to its average volume of 1,266,168. The company has a debt-to-equity ratio of 0.99, a current ratio of 4.75 and a quick ratio of 4.12. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 129.97, a price-to-earnings-growth ratio of 1.69 and a beta of 1.11. The stock has a 50 day moving average of $37.54 and a 200-day moving average of $40.87. Pacira Biosciences has a 12-month low of $34.64 and a 12-month high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.27. The business had revenue of $102.60 million for the quarter, compared to the consensus estimate of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Sell-side analysts expect that Pacira Biosciences will post 0.64 EPS for the current fiscal year.

In other Pacira Biosciences news, CEO David M. Stack sold 12,849 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kristen Marie Williams sold 6,252 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. HM Payson & Co. acquired a new stake in Pacira Biosciences in the second quarter valued at approximately $39,000. C M Bidwell & Associates Ltd. bought a new position in shares of Pacira Biosciences in the second quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its position in shares of Pacira Biosciences by 414.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after purchasing an additional 1,157 shares during the period. Amundi Pioneer Asset Management Inc. bought a new position in shares of Pacira Biosciences in the first quarter valued at approximately $65,000. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of Pacira Biosciences in the second quarter valued at approximately $71,000. Institutional investors own 99.10% of the company’s stock.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Article: Special Dividends

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.